Rapidly dividing and invasive cancer cells are strongly dependent on effective lysosomal function. Accordingly, transformation and cancer progression are characterized by dramatic changes in lysosomal volume, composition and cellular distribution. Depending on one's point of view, the cancer-associated changes in the lysosomal compartment can be regarded as friends or foes. Most of them are clearly transforming as they promote invasive growth, angiogenesis and drug resistance. The same changes can, however, strongly sensitize cells to lysosomal membrane permeabilization and thereby to lysosome-targeting anti-cancer drugs. In this review we compile our current knowledge on cancer-associated changes in lysosomal composition and discuss the consequences of these alterations to cancer progression and the possibilities they can bring to cancer therapy.
INTRODUCTION
Lysosomes are acidic (pH 4.5-5) catabolic organelles found in all mammalian cells except for mature erythrocytes. They are responsible for the disposal and recycling of worn out and damaged cellular macromolecules and organelles as well as the digestion of extracellular and foreign materials delivered to them by endocytosis, autophagy and phagocytosis [1] [2] [3] ( Figure 1 ). The digestion of the cargo is brought about by hydrolases residing in the lysosomal lumen, and the products are recycled back to the cytosol via diffusion and specific transport channels or released to the extracellular space by exocytosis.
Malignant transformation introduces series of changes in lysosomes and their function ( Figure 1 ). These include increased lysosomal biogenesis and hydrolase activity, changes in the lysosomal membrane composition and enhanced secretion of lysosomal contents to the extracellular space. [4] [5] [6] [7] Accordingly, increases in the expression and function of various lysosomal hydrolases are common in human tumors, and they often correlate with a higher risk of recurrence and poor prognosis. [8] [9] [10] In addition to their possible use as prognostic biomarkers, mounting evidence points to essential roles for extracellular lysosomal enzymes in cancer invasiveness, angiogenesis and progression, making these enzymes attractive targets for cancer therapy. 5, 10 By contrast, intracellular release of lysosomal hydrolases can trigger apoptosis or non-apoptotic lysosomal cell death providing a rational for cancer therapies aiming at destabilization of the lysosomal membranes. 11 Below, we review the fundaments of lysosomal biogenesis and composition, and assemble our current knowledge on cancer-associated changes in the expression and activity of lysosomal components with focus on the therapeutic opportunities they provide. We will focus here on those changes that are best studied and currently considered as putative therapeutic targets in cancer.
LYSOSOMAL BIOGENESIS AND COMPOSITION
Lysosome formation Lysosomal biogenesis requires a complex integration of the biosynthetic and endocytic pathways 2, 3, 12 ( Figure 2 ). The endolysosomal system is a dynamic network of vesicles connecting the plasma membrane to the lysosome. It starts from the budding of early endosomes from the plasma membrane and continues via a gradual maturation to late endosomes and finally to lysosomes. During this process that takes B30 min, lysosomes receive a number of essential proteins, including most of the lysosomal hydrolases, either directly from the Golgi complex or via exocytosis followed by endocytosis. Of these, the vacuolar H þ -ATPase (V-ATPase) pump at the limiting membrane gradually acidifies the maturing endosomes from pH around 6.2 in early endosomes to a final pH around 4.5-5 in mature lysosomes. 13, 14 The maturation process involves an inward budding of the limiting membrane resulting in numerous intraluminal vesicles. 15 The intraluminal vesicles function as important endosomal sorting stations and contain proteins (for example, endocytosed receptors) and lipids destined to cycling back to the plasma membrane or to the lysosomal degradation.
Synthesis and transport of lysosomal hydrolases Lysosomes contain over 50 hydrolases including proteinases, glycosidases, phosphatases, sulfatases, nucleases and lipases. Lysosomal hydrolases are synthesized in the rough endoplasmic reticulum as proforms and processed in the Golgi complex, where many of them are tagged with mannose-6-phosphate (M6P) residues and bind to specific M6P receptors (M6PRs) that target the complexes to clathrin-coated pits destined to early endosomes. 3 Upon endosomal maturation, the hydrolases are released in late endosomes as a result of decreasing pH and they continue their journey to the mature lysosomes, whose acidic pH provides them with optimal working conditions. Less characterized M6PR-independent lysosomal targeting pathways include transport of b-glucocerebrosidase by lysosomal integral membrane protein 2 (LIMP2 or LGP85), all the way from ER to lysosomes via the endosomal compartment, 16 and sortilin-mediated targeting of acid sphingomyelinase (ASM) and sphingolipid activator proteins directly to lysosomes. 17, 18 Extralysosomal roles of lysosomal hydrolases In addition to their central catabolic role, lysosomes can also mediate programmed cell death, cell membrane repair and tissue remodeling. [19] [20] [21] All of these processes involve regulated release of lysosomal hydrolases via processes such as lysosomal membrane permeabilization or lysosomal exocytosis/lysosomal secretion. Although lysosomal membrane permeabilization releases lysosomal hydrolases into cytosol, lysosomal exocytosis releases them into the extracellular space.
Lysosomal membranes Lysosomal membranes can be divided into the external limiting membrane and a number of intraluminal vesicles. Akin to other cellular membranes, their lipid composition is highly regulated with regard to lipid classes, saturation and chain length. 22 They are mainly made up of glycerophospholipids and sphingolipids and differ from other cellular membranes by having high amounts of bis(monoacylglycero)phosphate (BMP), 4-17% of the total lysosomal lipid depending on cell type and up to 70% of the lipid in the intraluminal vesicles. 23 The major function of BMP is associated with its localization to the intraluminal vesicles, where it serves as a docking lipid for soluble lipases allowing them to reach their substrates in the membrane. 1, 22 Lipases containing a positively charged lipid-binding domain (for example, ASM) bind directly to the negatively charged BMP, whereas most lipases do so via positively charged adaptor proteins (for example, SAPs). The suggested backbones of BMP synthesis include phosphatidylglycerol generated in the endoplasmatic reticulum and mitochondrial cardiolipin, but its exact biosynthetic pathway is still unclear. 1 In addition to lysosomal integral membrane protein 2 (also known as SCARB2) and V-ATPase, lysosomal membranes contain a variety of membrane-associated proteins including lysosomalassociated membrane proteins 1 and 2 (LAMP1 and LAMP2), LIMP1 (also known as CD63 or tetraspanin) as well as numerous less characterized membrane components and transport proteins. 24 A large fraction of lysosomal membrane proteins travel from the trans-Golgi network to plasma membrane via the default secretory pathway and reach the lysosomal compartment through endocytosis. 25 Alternatively, they can travel directly from the trans-Golgi network to the endolysosomal membranes along multiple as yet poorly defined pathways.
3 LAMP1 and LAMP2 contribute to about half of the lysosomal transmembrane proteins and they are essential for the maintenance of the structural integrity of the lysosomal compartment. 26, 27 LAMPs are highly homologous proteins with short cytoplasmic C-terminal tails and highly glycosylated luminal N-terminal domains. Their glycosylated tails form a sugar coat called glycocalix to the inner surface of the limiting membrane that protects the membrane from degradation by lysosomal hydrolases. LAMPs also serve overlapping and distinct functions in lysosomal trafficking and exocytosis, chaperone-mediated autophagy, autophagosomelysosome fusion and cholesterol transport. [27] [28] [29] [30] Transcriptional control of lysosomal biogenesis The understanding of the transcriptional control of lysosomal biogenesis has only just begun to emerge. Transcription factor EB (TFEB), which positively regulates the expression of many genes encoding for lysosomal hydrolases and lysosomal membrane proteins, has recently been identified as the major regulator of lysosomal biogenesis. 31, 32 Interestingly, its activity is controlled in opposite ways by two cancer-associated kinases, mitogenactivated protein kinase 1/extracellular signal-regulated kinases (MAPK1/ERK2) and mammalian target of rapamycin complex 1. MAPK1/ERK2-mediated phosphorylation of TFEB blocks its nuclear transport, 33 whereas, activation of mammalian target of rapamycin complex 1 can lead to nuclear transport-inducing phosphorylation of TFEB. 32 These studies indicate that the biological function of TFEB is under complex regulation and that kinase-mediated control of TFEB and other transcription factors regulating lysosomal biogenesis have a major role in their cancer-associated changes.
OPPOSITE ROLES OF CATHEPSINS IN TUMOR PROGRESSION; LOCALIZATION MATTERS
Cathepsins are powerful hydrolases that can be divided into three subgroups depending on the amino acid located in their catalytic dyad: aspartate cathepsins (cathepsins D and E), cysteine cathepsins (cathepsins B, C, F, H, K, L, O, S, V/U/L2, W, X/Z/Y) and serine cathepsins (cathepsins A and G). 34 Akin to most other lysosomal hydrolases, they function optimally at pH around 4.5 or lower. With respect to their secretion to the extracellular space and leakage to the cytosol, it is important to note that many cysteine cathepsins can also be active at higher pH, albeit often with changed functional parameters such as enzyme kinetics and substrate specificity. 35 Increased expression, activity and secretion of cathepsins lead to enhanced tumor growth, invasion and angiogenesis. 4, 36, 37 Accordingly, several cathepsins are overexpressed in variety of cancers, often both in the tumor cells and in tumor-associated leukocytes, fibroblasts, osteoclasts, myoepithelial cells and endothelial cells. 4 The tumor promoting effects of cathepsins have been mainly assigned to their proteolytic activities outside the cell, whereas increased cysteine cathepsin activity in the lumen of lysosomes enhances the proteolysis of LAMP1 and LAMP2 and leads to the destabilization of lysosomal membranes thereby sensitizing cells to various stresses and limiting cell survival. 26 Upon destabilization of lysosomal membranes, cathepsins leak to the cytosol where they can activate either the mitochondrial apoptosis pathway or trigger non-apoptotic cell death, a mode of cell demise that can effectively kill even highly apoptosis resistant cancer cells. 7, 38 Below we highlight the cancerassociated roles of individual cathepsins.
Cathepsin D (encoded by CTSD)
Cathepsin D is an aspartate cathepsin and belongs to the pepsin superfamily of proteases. 39 First reports of increased levels of cathepsin D in human cancer date back to the 1980s. 40, 41 Since then plentiful studies have confirmed these findings in the majority of solid cancers. 37, 42 Furthermore, positive correlations between cathepsin D expression and tumor size, tumor grade, metastasis, poor prognosis, chemoresistance and risk of recurrence have been reported. 42, 43 Accordingly, cathepsin D plays an essential role in the multiple steps of tumor progression by stimulating cancer cell proliferation and survival, fibroblast outgrowth and angiogenesis. 37, 43 Interestingly, these cancerpromoting functions of cathepsin D appear to be largely independent of its proteolytic activity suggesting that the protein or its unprocessed precursors have cytokine or growth factor-like activities. 37, 43 Fittingly, pro-cathepsin D and its propeptide can induce the activation of the mitogen-activated protein kinase (MAPK-ERK) signaling pathway, cytokine secretion and expression of genes encoding for proteins supporting proliferation, metastasis and angiogenesis. [42] [43] [44] The importance of the pro-form rather than the active form of cathepsin D in cancer progression challenges the development of cathepsin D targeting anti-cancer drugs since small molecule enzyme inhibitors are not likely to be effective.
Cathepsin B (encoded by CTSB) Cathepsin B is a cysteine cathepsin of the papain superfamily, whose increased expression has been widely reported in most cancer types, often both in cancer cells themselves as well as in tumor-associated macrophages and fibroblasts. 4, 45, 46 In line with the idea that cathepsin B enhances invasion and metastasis, it is often localized at the surface of tumor cells, and its expression is predominantly increased in the cells at the invasive edge of the tumors. In general, increased cathepsin B levels detected by Figure 2 . The endocytic system. The endolysosomal system is a dynamic network of vesicles connecting the plasma membrane to the lysosome with decreasing pH during maturation. The maturation process involves an inward budding of the limiting membrane resulting in numerous intraluminal vesicles. The intraluminal vesicles function as important endosomal sorting stations and contain proteins and lipids destined to cycling back to the plasma membrane or to the lysosomal degradation. Lysosomes receive most of their hydrolyzes and membrane proteins either directly from the trans-Golgi network or via exocytosis followed by endocytosis. The highly glycosylated proteins at the limiting lysosomal membrane protect the membrane from degradation by lysosomal hydrolases.
immunohistochemistry correlate well with higher mRNA levels pointing to a transcriptional upregulation of cathepsin B encoding CTSB gene. 47 Accordingly, transformation of fibroblast and/or epithelial cells by activated Ras, Src or ERBB2 oncogenes increases the levels of CTSB/CtsB mRNAs, protein and proteolytic activity and promotes pericellular distribution of lysosomes. 26, [48] [49] [50] Moreover, ErbB2-induced upregulation of cathepsins B (and L) renders noninvasive breast cancer cells highly invasive in a three-dimensional Matrigel invasion model. 50 The ErbB2-induced expression of cathepsin B-encoding CTSB gene appears to be independent of TFEB, 50 the major regulator of the transcription of lysosomal genes. 31 Instead, ErbB2 activates a signaling network consisting of PAK4, cdc42bpb, PKCa and MAPK-ERK2 serine-threonine kinases that activates a myeloid zinc-finger transcription factor 1 (MZF1), which in turn binds to an ErbB2-induced enhancer element in the first intron of CTSB gene in vivo. 50 Interestingly, MAPK-ERK2 activity, which is essential for the ErbB2-induced activation of myeloid zinc-finger transcription factor 1 and expression of CTSB, inhibits the nuclear import of TFEB. 51 It remains to be studied whether similar transcriptional switch occurs in response to other CTSB-activating oncogenes and whether the transcription of other lysosomal genes also switches from TFEB-dependency to dependency on myeloid zinc-finger transcription factor 1 or other oncogene-activated transcription factors.
The active role of cathepsin B in tumorigenesis is strongly supported by murine cancer models. In the RIP1-Tag2/RT2 (RT2) pancreatic islet cell carcinogenesis model, the multiple pancreatic islet tumors driven by the expression of oncogenic SV40 T-antigen in insulin producing b-cells express high levels of cathepsin B. 52, 53 Crossing of these mice to a Ctsb-deficient background results in strongly impaired tumor formation, tumor cell proliferation, angiogenesis and invasiveness. The suggested molecular basis in this model includes secretion of cathepsin B from tumor cells and tumor-associated macrophages and direct cathepsin B-mediated cleavage of extracellular matrix components, E-cadherin and urokinase plasminogen activator propeptide, the latter leading to the activation of a potent proteolytic cascade involving sequential activation of urokinase plasminogen activator, plasmin and various matrix metalloproteases. 52, [54] [55] [56] [57] Similarly, Ctsb deficiency significantly delays the onset and growth of primary mammary tumors and their lung metastases in murine mammary tumor virus-polyoma middle T antigen (PyMT) transgenic mice. 58 Vice versa, cathepsin B overexpression in PyMT mice promotes mammary tumor growth and metastasis. 59 These data reveal extracellular cathepsin B as an attractive target for cancer therapy. Supporting this notion, a non-cell permeable cathepsin B specific inhibitor CA-074 has given promising results in murine models of metastatic melanoma and breast cancer. 60, 61 Contrary to the strong tumor-promoting properties of cathepsin B, increased cathepsin B (and L) activity in the lumen of the lysosomes may form an Achilles heal for the cancer cells via the cleavage of LAMP1 and LAMP2, and subsequent destabilization of lysosomal membranes, decreased stress tolerance and sensitization to drugs that activate the lysosomal cell death pathway. 26, 62 Thus, high cathepsin B expression in tumor cells may prove to be a useful biomarker for the responsiveness to lysosome-targeting therapies.
Cathepsin L (encoded by CTSL1) Cathepsin L is another ubiquitously expressed cysteine cathepsin that is frequently overexpressed in various human tumors. 46 It enhances migration and invasion by decreasing cell-cell adhesion and increasing extracellular matrix degradation. 4, 36 Its identified substrates that include extracellular matrix proteins, such as laminin, fibronectin and collagens as well as E-cadherin and proheparanase. 52, [63] [64] [65] [66] Studies on the role of cathepsin L in angiogenesis are somewhat contradicting. 65 Supporting its role in angiogenesis, cathepsin L expression is significantly associated with the neovasculature of astrocytic tumors, 67 and cathepsin L specific inhibitor NSITC displays potent antiangiogenic activity in chick chorioallantoic membrane and mouse matrigel models of angiogenesis in vitro. 68 Nevertheless, in the RT2 mouse model of pancreatic islet cell carcinogenesis Ctsl deletion has no effect in the angiogenic switch even though it effectively impairs tumor growth and invasiveness. 52 Cathepsin L has an additional tumorigenic activity in the nucleus. An isoform of cathepsin L that lacks the signal peptide necessary for the lysosomal targeting migrates to the nucleus where it cleaves histone H3 and transcription factors such as the CCAAT-displacement protein/cut homeobox (CDP/Cux), thereby altering cell cycle progression and gene expression patterns and contributing to oncogenic transformation. [69] [70] [71] [72] In colorectal cancer increased nuclear versus lysosomal localization of cathepsin L correlates with advanced tumor stage and poor prognosis. 73 As for cathepsin B, specific inhibitors have also been developed for cathepsin L. 74, 75 Of these, the most promising metastasis and/or invasion blocking compounds include CLIK-148 and FF-FMK. 65 FF-FMK, which can also inhibit cathepsin B at higher concentrations, decreases the invasion of human oral squamous cell carcinoma cell lines in vitro, 76 and oral administration of CLIK-148 inhibits human melanoma A375 cell metastasis to bone but not to liver or muscle in a xenograft mouse model. 77 Several additional studies support the bone degradative function of cathepsin L, making it a possible target molecule in the treatment of metastatic bone disease. 78 The usefulness of cathepsin L as a therapeutic target for cancer treatment has, however, been questioned by studies showing that its deficiency or inactivation promotes tumor progression in mouse skin cancer models [79] [80] [81] as well as in intestinal epithelia. 82 The molecular explanation for this tumor suppressive role of cathepsin L may be its essential role in the negative regulation of the recycling of growth factors and their receptors from the endocytic compartment back to the plasma membrane. 83 Cathepsin K (encoded by CTSK) Cysteine cathepsin K has high collagenolytic and osteolytic activity. It is predominantly expressed in osteoclasts, where it is the key protease responsible for bone resorption and bone metabolism. 84 Correspondingly, inactivating mutations in human cathepsin K gene (CTSK) result in pycnodysostosis characterized by short stature, skull deformities and skeletal abnormalities. 85 Cathepsin K expression is activated in breast and prostate carcinomas with higher expression levels in bone metastases as compared with primary tumors. [86] [87] [88] Cathepsin K inhibitors (CKI, AFG495 and Odanacatib), which have been successfully used to treat osteoporosis-associated bone loss, 84, 89 reduce breast cancerinduced osteolysis and skeletal tumor burden in a mouse model of skeletal metastasis. 87 Notably Odanacatib is currently on phase III trial as a treatment to reduce the risk of breast cancer-induced bone metastasis (http://www.cancer.gov/drugdictionary). In melanoma, cathepsin K expression correlates with advanced metastatic disease, 90 and pharmacological inhibition of cathepsin K with Boc-I reduces melanoma cell invasion through the Matrigel basement membrane matrix. 90 Inhibition of cathepsin K in this model results in the accumulation of internalized collagen in the lysosomal compartment, suggesting that cathepsin K is essential for the effective intracellular degradation of phagocytosed matrix proteins also outside the bone.
Other cysteine cathepsins The expression of cysteine cathepsins S, F, H, O, V (also known as L2 or U) and Z (also known as Y or X) is also increased in human cancers. However, relatively little is known about their regulation Cancer-associated lysosomal changes T Kallunki et al or function. Cathepsin S may function in angiogenesis by degrading anti-angiogenic, type IV collagen derived peptides and generating pro-angiogenic peptides by cleavage of laminin-5. 91, 92 Accordingly, genetic inactivation of cathepsin S encoding CTSS gene in the RT2 mouse model of pancreatic cancer leads to impaired tumor formation and impaired angiogenesis. 52 In the same model system, genetic inactivation of CTSH (cathepsin H) also significantly impaired angiogenic switching of the premalignant hyperplastic islets and resulted in a reduction in the subsequent number of tumors. 93 Moreover, the tumor burden in CTSH null RT2 mice is significantly reduced, in association with defects in the blood vasculature and increased apoptosis. Finally, simultaneous depletion of cathepsins B and Z results in synergistic antitumor effects in the murine PyMT breast cancer model, suggesting that most, if not all, cysteine cathepsins may posess tumor-promoting features. 94 Pharmacological targeting of cysteine cathepsins More than one cathepsin is usually upregulated upon oncogenedriven transformation in vitro in pre-clinical murine cancer models as well as in human cancer. Their highly overlapping substrate specificities and functions in tumorigenesis suggest thus that a combined inhibition of their activities might be required for an efficient cancer therapy. Accordingly, a single genetic inactivation of Ctsb or Ctsz in the PyMT oncogene-induced mammary carcinomas delays only slightly the appearance of tumors and lung metastasis, whereas their combined inactivation results in a significant delay in tumor growth and reduction in the number and size of metastases. 94, 95 In line with this, a cell-permeable broad-spectrum cysteine cathepsin inhibitor JPM-OEt is much more effective than single depletions of Ctsb, Ctsl or Ctss in reducing angiogenic switching in the murine RT2 pancreatic carcinoma model. 52, 92 By contrast, JPM-OEt shows poor efficacy in the PyMT murine breast cancer model, 96 and fails to reduce metastasis in the breast cancer bone metastasis model in which the non cell-permeable CA-074 is effective. 61 These results may be simply due to differential bioavailability of the drugs in different tissues. 96 Alternatively, different cysteine cathepsins may have opposing roles in some cancers, or the ability of JPM-OEt to enter the cell and inhibit intracellular cathepsins may stabilize lysosomal membranes and provide cancer cells with a survival advantage that counteracts the effects of extracellular inhibition of cathepsins. However, the available preclinical data strongly encourage the continuing development of broad-spectrum cysteine cathepsin inhibitors as cancer therapeutics, but clearly more basic research on the anticancer effects of individual cathepsins and their localization is needed to find the optimal treatment modalities.
GLYCOSIDASES REGULATE ANGIOGENESIS AND METASTASIS Heparanase (encoded by HPSE)
Heparanase is an endo-b-D-glucuronidase and the predominant mammalian enzyme-degrading heparan sulfate. Heparanase is processed in late endosomes and lysosomes, and localizes primarily to these organelles as well as to the extracellular matrix. Heparanase-mediated cleavage of heparan sulfate side chains from the heparane sulfate proteoglycans leads to the disassembly of the extracellular matrix and is associated with tissue remodeling, cell movement, cancer progression, metastasis and angiogenesis. 97 Heparan sulfate binds and sequesters several growth factors, cytokines and chemokines into the extracellular matrix and cell surface, and its cleavage will therefore increase their release and tissue availability. 98, 99 Heparanase expression is enhanced in numerous human cancers, 6, 100, 101 and its activity positively correlates with the metastatic potential of tumor cells, attributes to the remodeling of the extracellular matrix and promotes neovascularization. 102, 103 Cancer cells secrete heparanase in response to nucleotides such as ATP, ADP and adenosine with similar kinetics than cathepsin D. 104 Moreover, heparanase is found in the body fluids of patients with metastatic cancer, indicating its secretion in vivo. 105, 106 Heparan and its derivatives, sulfated oligoshaccarides and suramin as well as suramin analogs show potent antimetastatic activity in mouse models of metastatic cancers as well as in clinical trials. [107] [108] [109] [110] PI-88, a heparanase inhibitor with potent antiangiogenic activity, 110, 111 is currently on phase III clinical trial as 'the adjuvant treatment of subjects with hepatitis virus-related hepatocellular carcinoma after surgical resection' (http://www. cancer.gov/drugdictionary). Moreover, a novel heparanase and angiogenesis inhibitor, a heparan sulfate mimetic PG545, has shown promise in numerous pre-clinical murine cancer models and is now on phase I clinical trial. 112 When designing clinical trials for heparanase inhibitors, it should be taken into account that contrary to most other cancer types, multiple large array data sets reveal a highly significant decrease in HPSE mRNA levels in colon cancer (www.oncomine.org).
Neu1 sialidase 1 (encoded by NEU1) Sialidases (also known as neuraminidases) cleave sialic acids from gangliosides and glycoproteins. There are four mammalian sialidases (Neu1, Neu2, Neu3 and Neu4), of which Neu1 is predominantly localized in lysosomes. 113 Neu1 activity is decreased in oncogene-transformed rat fibroblasts and mouse adenocarcinoma colon 26 cells with inversed correlation between Neu1 expression and metastatic potential. 114 Similarly, its ectopic expression and depletion in the HT-29 human colon cancer cells inhibits and enhances liver metastasis in a mouse xenograft model, respectively. 115 The metastasis suppressing function of Neu1 has been suggested to be due to its sialyation of b4 integrin resulting in decreased b4 phosphorylation and signaling. 115 Furthermore, Neu1 is a negative regulator of lysosomal exocytosis, which is likely to contribute to its antimetastatic activity. 29 Excessive lysosomal exocytosis in Neu1-deficient cells can be inhibited by silencing of LAMP1, suggesting that oversialylated LAMP1 is a key mediator of excessive exocytosis of lysosomal proteases in these cells. 29 Increased sialyation of LAMP1 and LAMP2 is found in some human cancers, and in colon cancer, it strongly correlates with the metastatic potential. 116 Because sialyated LAMPs are essential for the lysosomal membrane stability, 24 the excessive sialyation of LAMPs may also protect lysosomal membranes from destabilization and thereby enhance cancer cell survival. The fact that the inactivation of this enzyme promotes cancer progression makes sialidase a challenging target for cancer treatment.
LYSOSOMAL SPHINGOLIPID CATABOLISM CONTROLS LYSOSOMAL INTEGRITY AND CELL SURVIVAL
Sphingolipids are sphingosine-based lipids, whose 'bioactive' properties have made them interesting for cancer research. 117, 118 They modulate diverse physiological and pathological processes including cell growth, cell death, autophagy and angiogenesis. Sphingomyelinases and ceramidases are key enzymes of sphingolipid catabolism, as they regulate the formation and degradation of ceramide, one of the most intensely studied classes of sphingolipids with pro-apoptotic and growth inhibitory activities. 119 Human cells express several forms of these enzymes that possess varying pH optima. Here, we concentrate only on the lysosomal forms that act in low pH, that is, ASM and acid ceramidase.
Acid sphingomyelinase (encoded by SMPD1) The intraluminal lysosomal vesicles are the major sites for the degradation of sphingomyelin by ASM. ASM is a water-soluble glycoprotein with positively charged regions that facilitate its Cancer-associated lysosomal changes T Kallunki et al binding to negatively charged lipids such as BMP, a binding which greatly increases ASM activity by bringing the enzyme to the proximity of its neutral substrate in the intraluminal lysosomal vesicles. 120 Furthermore, the association of ASM with membranes protects it from proteolytic degradation by lysosomal proteases. 121 Sphingolipids and their metabolites regulate cell survival with diverse mechanisms that are not fully understood. The proapoptotic activity of ASM is largely attributed to the localization of the enzyme to the plasma membrane in response to various stresses. 122, 123 The subsequent generation of ceramide at the plasma membrane contributes to the formation of ordered membrane domains that can enhance apoptosis induction by death receptors. [122] [123] [124] By contrast, lysosomal ASM may have an opposite effect on cell survival as its activity is essential for the maintenance of the lysosomal membrane integrity. 125 Notably, ASM may also contribute to cancer progression by a mechanism involving ceramide-mediated activation of pre-pro cathepsin D to enzymatically active isoforms of cathepsin D. 126 Owing to the well-established pro-apoptotic properties of ceramide, ASM has been mainly considered as a negative regulator of cancer progression. 119, 127 Accordingly, our database search revealed a highly significant cancer-associated reduction in ASM, encoding SMPD1 mRNA levels in multiple studies of gastrointestinal, hepatocellular, salivary gland, renal and head and neck carcinomas, whereas as a modest but significant increase in SMPD1 expression was found only in single studies of hairy cell leukemia and smoldering myeloma (www.oncomine. org). The decreased SMPD1 expression in several cancers may, however, contribute to the increased sensitivity of transformed cells to lysosomal cell death pathways. On the other hand, the SMPD1 mRNA levels do not necessarily reflect the levels of ASM protein whose binding to BMP, stability and activity can be enhanced by heat shock protein 70, 125 which is commonly relocated to the plasma membrane and thereby also to the endolysomal compartment of cancer cells. 128, 129 Acid ceramidase (encoded by ASAH1) Lysosomal ceramide is further degraded by acid ceramidase to sphingosine that diffuses rapidly out of the lysosomes and can be converted to sphingosine-1-phosphate. 130, 131 The inhibition of acid ceramidase has received much attention in anticancer therapy due to the cell death and cell survival promoting attributes of ceramide and sphingosine-1-phosphate, respectively. 127 Furthermore, a recent study identified acid ceramidase as a positive regulator of prostate cancer invasion via a mechanism involving sphingosine 1-phosphate-mediated upregulation of CTSB expression. 132 The expression of ASAH1 has been reported to be upregulated in prostate cancer, 133 and downregulated in thyroid cancer. 134 Additionally, our database search reveals significantly increased expression of ASAH1 in centroblastic, hairy cell and mantle cell lympomas as well as in glioblastoma, and decreased expression especially in leukemias, lung cancers and sarcomas (www.oncomine.org). In spite of the strong experimental evidence linking acid ceramidase activity to increased cell survival, convincing in vivo evidence supporting its protumorigenic effect is still lacking. By contrast, the ASAH expression correlates with a better prognosis in ER-positive breast cancer. 135 Thus, more in vivo studies are clearly needed in order to evaluate acid ceramidase as a putative cancer target.
Pharmacological inhibition of sphingomyelin catabolism Several clinically relevant drugs, most notably the large group of cationic amphiphilic drugs (tricyclic antidepressants, malaria drugs, antihistamines, and so on), induce a functional loss of ASM activity. 121 As basic substances, cationic amphiphilic drugs accumulate in acidic lysosomes where they interfere with the electrostatic attraction between ASM and its docking lipid BMP on the surface of intralumenal vesicles promoting proteolysis of the enzyme. 1 These drugs are, however, not specific for ASM, but inhibit also acid ceramidase and lysosomal phospholipases. 127 Notably, Desipramine, a well-established inhibitor of ASM, destabilizes lysosomal membranes in a manner similar to the RNAi-mediated depletion of Smpd1. 125 Furthermore, most, if not all, cationic amphiphilic drugs are capable of reverting multidrug resistant phenotype in cancer cells. 11, 136 It is, however, unclear whether the disturbance of sphingolipid metabolism contributes to this effect, or whether it is mediated via the cationic neutralization of lysosomal pH or other yet undefined activities of these drugs. Taken together, our knowledge of the actual roles of ASM and acid ceramidase in tumor development and progression are sparse and calls for the development of more specific enzyme inhibitors suitable for the use in in vivo models of cancer.
V-ATPASE REGULATES ALL ASPECTS OF LYSOSOMAL BIOLOGY
The maintenance of highly acidic pH in the lysosomal lumen is essential for the proper function of the lysosomes. The pH gradient between cytosol and lysosomal lumen is generated by the action of a V-type ATPase that uses the free energy of ATP hydrolysis to drive protons against their electrochemical gradient into the lysosome.
137 This 14-subunit protein complex is composed of a soluble ATP-hydrolyzing (V1) and a transmembrane H þ -translocating (V0) subcomplexes. The V-ATPase activity does not only ensure lysosomal digestive functions but is also essential for the lysosomal calcium homeostasis as well as lysosomal trafficking and fusion events. 137, 138 Thus, the inhibition of V-ATPase activity impairs endocytosis and autophagy and may even disrupt lysosomal membrane integrity.
In spite of the cancer-associated increase in acid production, the entire V-ATPase complex does not seem to be overexpressed in neoplastic cells. Instead, the increased expression of specific subunits may contribute to altered activity of the pump. For example, overexpression of the gene encoding for the V1 subunit C (ATP6V1C1) in oral squamous carcinoma cells has been suggested to enhance the pump activity by promoting the assembly of V0 and V1 subcomplexes. 139 On the other hand, cisplatin-resistant cell lines have been reported to upregulate the V0 subunit-c (ATP6V0C), 140 and changes in the V0 subunit-a isoform expression pattern affect the subcellular localization of the V-ATPase, the a3 isoform favoring the localization at the plasma membrane. 141 The plasma membrane V-ATPase acidifies the extracellular space thereby easing the action of cathepsins on extracellular matrix and enhancing cancer cell invasion. 142 Accordingly, depletion of a3 isoform in highly invasive breast cancer or melanoma cells results in decreased cytosolic pH and reduced invasiveness. 143, 144 Even though the specific targeting of the differently assembled V-ATPase pumps is not possible with the tools available today, the existing V-ATPase inhibitors may prove useful in cancer therapy. Several different types of V-ATPase inhibitors exist and they can induce programmed cell death and cell cycle arrest in various cancer cells, inhibit invasion, revert multidrug-resistant phenotype and some of them have even been shown to decrease xenograft tumor growth in vivo. 13, 145, 146 Of these, special attention has been given to benzolactone enamides that can possibly even discriminate between different V-ATPases and thus are believed to serve as good basic compounds for the development of V-ATPase targeting antitumor agents. 147, 148 Interestingly, in a synthetic lethal screen, benzolactone enamide RTA203 and taxol synergistically killed H1155 cancer cells at doses where the single compounds only had minor effects, 149 supporting the idea of Cancer-associated lysosomal changes T Kallunki et al possibly using the V-ATPase inhibitors in a combination therapy.
The clinical use of the potent V-ATPase inhibitors may, however, be limited by their toxicity. Thus, it is interesting to note that clinically safe and well-tolerated inhibitors of H þ , K þ -ATPase, the enzyme involved in proton secretion in the stomach (for example, omeprazole and esomeprazole), also inhibit V-ATPase and induce lysosomal cancer cell death in vitro.
150 Furthermore, such compounds show efficacy in murine tumor models resulting in improved chemotherapy response and tumor control.
151,152

PERSPECTIVES
As reviewed above, numerous cancer-associated changes in lysosomal composition and function have a major role in cancer progression (Figure 3) . Thus, lysosomes with their arsenal of hydrolytic enzymes are emerging as an area of great interest in the field of oncology. Various in vivo and in vitro models support the inhibition of cysteine cathepsins, V-ATPase and heparanase as means to inhibit invasion and metastasis of specific cancer types. In case of cathepsins, it is clear that more than one cathepsin type should be inhibited because of their redundant hydrolytic activities. Thus, a better inhibition of invasiveness could probably be achieved by the inhibition of lysosomal exocytosis. Such an approach could also have the additional benefit that it would not reduce the activity of cathepsins inside the lysosomes where they can compromise cancer cell survival by destabilizing the lysosomal membranes. Even though the understanding of the cancerassociated lysosomal exocytosis has just begun to emerge, it carries a great potential for future anticancer therapeutics. Other emerging research areas that are likely to reveal novel lysosomeassociated therapeutic targets are the lysosomal pH regulation and lipid metabolism both of which are essential for lysosomal stability and cytoprotective autophagy.
Based on the dual role of lysosomes in cancer progression, the optimal lysosome-based anticancer treatment should decrease the extracellular and increase the lysosomal content of active cathepsins thereby inhibiting invasion and enhancing lysosomal membrane permeabilization. This approach, if possible, could turn our enemies into our friends. Cancer-associated lysosomal changes T Kallunki et al
